FDA Peptide Vote: 6 of 7 Recommended
On July 23-24, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend 6 of 7 nominated peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — for the 503A Bulk Drug Substances List. DSIP/emideltide was rejected. This was a recommendation, not approval and not legalization: the rules don't change until formal FDA rulemaking follows.
(of 7 nominated)
(DSIP / emideltide)
Compound Today
How the Vote Went (July 23–24, 2026)
Over two days the PCAC voted to recommend 6 of the 7 nominated peptides for the Section 503A bulks list — and did so over the objection of the FDA's own review staff, who had recommended against all seven, citing incomplete chemical characterization, thin human data, and immunogenicity concerns.
| Peptide | Nominated for | PCAC vote | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis / wound healing | 8–6, 1 abstention | ✅ Recommended |
| KPV | Wound healing / inflammation | 8–6, 1 abstention | ✅ Recommended |
| TB-500 | Wound healing | 8–6, 1 abstention | ✅ Recommended |
| MOTS-c | Obesity / osteoporosis | 7–5, 2 abstentions | ✅ Recommended |
| Epitalon | Anti-aging | Affirmative | ✅ Recommended |
| Semax | Opioid withdrawal / cognition | Affirmative | ✅ Recommended |
| DSIP (emideltide) | Insomnia | 7–6 against | ❌ Rejected |
Vote tallies verified against FDA advisory-committee materials and trade coverage (NCPA, Pharmaceutical Executive, Boesen & Snow Law), Jul–Aug 2026. Where a precise public tally was not reported for a peptide, its outcome is shown as an affirmative recommendation. See Sources below.
A PCAC vote is advisory and non-binding. It does NOT make any of these peptides an FDA-approved drug, and it does NOT make them legal to buy or compound today. Before anything changes, the HHS Secretary must act and the FDA must complete formal notice-and-comment rulemaking to move each compound from Category 2 onto the 503A list — realistically 8–18 months out, and potentially longer. Until that final rule is in place, licensed pharmacies still cannot legally compound these peptides, no clinical benefit is established, and any "FDA approved" claim is false.
What Was Voted On
BPC-157 (ulcerative colitis), KPV (inflammation) and TB-500 (wound healing) were each recommended for the 503A bulks list on split 8–6 votes; MOTS-c (obesity) followed at 7–5. Four for four on Day 1.
Semax (opioid withdrawal / cognition) and Epitalon (anti-aging) were recommended on affirmative votes. Emideltide / DSIP (insomnia) was the lone rejection, failing 7–6. All had been Category 2 (barred from compounding) since the 2023 reclassification.
FDA's own career reviewers had urged the committee to reject all seven, citing incomplete chemical characterization, thin human data and immunogenicity risk. The advisory panel recommended six anyway — a recommendation the agency is not bound to follow.
This vote covered ONLY the 503A list (licensed pharmacies serving individual patients). The 503B outsourcing-facility status remains unresolved. Even though 503A inclusion was recommended, large-scale commercial compounding (telehealth supply at scale) requires separate 503B action.
What the Data Shows
Key Takeaways
- PCAC met July 23-24, 2026 at FDA White Oak and recommended 6 of 7 peptides for the 503A bulks list
- BPC-157, KPV and TB-500 each cleared on split 8–6 votes (one abstention); MOTS-c passed 7–5
- Epitalon and Semax were recommended on affirmative votes
- DSIP / emideltide (insomnia) was the only rejection, failing 7–6 against
- The panel recommended these over the objection of FDA's own reviewers, who advised against all seven
- The vote is advisory and NON-BINDING — it is not FDA approval and not legalization
- 503B outsourcing-facility status (commercial-scale supply) remains separate and unresolved
- Whether — and when — the HHS Secretary and FDA adopt the recommendation through formal rulemaking (realistically 8–18 months, possibly longer)
- Whether 503B outsourcing-facility status follows for commercial-scale supply
- The precise public vote tallies for Epitalon and Semax (recorded here as affirmative recommendations)
- How compounding pricing reshapes if and when licensed pharmacies can legally make these
- Whether enforcement against gray-market research-peptide vendors intensifies
Frequently Asked Questions
What is the FDA July 2026 peptide hearing?
On July 23-24, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven nominated peptides for the Section 503A Bulk Drug Substances List: BPC-157 (8-6, one abstention), KPV (8-6), TB-500 (8-6), MOTS-c (7-5, two abstentions), and — on affirmative votes — Epitalon and Semax. DSIP/emideltide was rejected (7-6 against). Critically, a PCAC vote is a non-binding recommendation, NOT FDA approval and NOT legalization: the HHS Secretary plus formal notice-and-comment rulemaking must still act before any licensed pharmacy can legally compound these, realistically 8-18 months out and possibly longer. They are not FDA-approved drugs today.
Will BPC-157 be legal to compound after this hearing?
Not yet, and not automatically. On July 23, 2026 PCAC voted 8-6 (one abstention) to RECOMMEND adding BPC-157 to the 503A list — but that recommendation is advisory and non-binding. It is not FDA approval and it does not make BPC-157 legal to compound today. The HHS Secretary must act and the FDA must complete notice-and-comment rulemaking before any licensed 503A pharmacy can compound BPC-157 with a valid prescription, realistically 8-18 months away. 503B outsourcing-facility status (commercial-scale supply for telehealth providers) is a separate process not addressed at this meeting.
Why are CJC-1295 and Ipamorelin not on the agenda?
They were moved to Category 2 in 2023 and became part of an industry lawsuit against the FDA over the reclassification. They are not listed for the July 2026 PCAC review, but per HHS Secretary Kennedy's peptide-reclassification effort, reinstatement is widely expected on a later docket. No specific date is confirmed as of April 2026.
What about Thymosin Alpha-1?
Same status — restricted in 2023, part of the litigation, not on the July 2026 agenda but expected to return to compounding access on a future docket. Practitioners and patients should monitor PCAC announcements through 2027.
How can I influence the outcome?
The July 2026 comment window and the PCAC vote have closed, but the process is not over. The recommendation now moves to the HHS Secretary and to FDA rulemaking, which carries its own public notice-and-comment period. Watch regulations.gov (docket FDA-2025-N-6895) and FDA advisory-committee announcements; patient testimony, prescriber documentation, and peer-reviewed evidence still factor into the final rule.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
Primary & Trade Coverage
The July 23–24, 2026 vote outcomes and tallies on this page are drawn from the FDA's own advisory-committee materials and independent trade and legal coverage of the meeting.
- FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting
Official meeting page, agenda and briefing materials (fda.gov). - NCPA — FDA advisory committee nominates six peptides for pharmacies to compound
Confirms six recommended, emideltide rejected, and that the votes are non-binding pending HHS action and rulemaking. - Pharmaceutical Executive — FDA panel votes to loosen restrictions on peptides
Reports the Day-1 tallies: BPC-157, KPV, TB-500 at 8–6–1 and MOTS-c at 7–5–2, and that the votes are not FDA approval. - Boesen & Snow Law — The peptide vote heard round the compounding world
Legal analysis: BPC-157 8–6–1, emideltide failed 7–6, FDA career staff had opposed all seven, and the multi-stage rulemaking timeline ahead.
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →Educational purposes only. Not medical advice.
Regulatory status of compounded peptides evolves rapidly. Verify current FDA guidance and applicable state pharmacy law before relying on this page for legal interpretation.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.